Experienced in Coarctation of the Aorta

Weiwei Xiao

Shenzhen, CN 
Experienced in Coarctation of the Aorta
Shenzhen, CN 
OverviewLocationsClinical Research

Overview

Weiwei Xiao practices in Shenzhen, China. Xiao is rated as an Experienced expert by MediFind in the treatment of Coarctation of the Aorta. Their top areas of expertise are Nasopharyngeal Carcinoma, Colorectal Cancer, Dry Mouth, and Mosaicism.

Their clinical research consists of co-authoring 62 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Coarctation of the Aorta.

Locations

Shenzhen, China
Other Locations
State Key Laboratory Of Oncology In South China, 651, East Dongfeng Road, Guangzhou, 510060, China
Guangdong Provincial Key Laboratory Of Tropical Disease Research, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Neoadjuvant PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients
Neoadjuvant PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Drug
Study Drug: Toripalimab
Study Phase: Phase 2
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2024
Intervention Type: Radiation, Drug, Procedure
Study Drugs: PD-1 Antibody, Oxaliplatin, Capecitabine
Study Phase: Phase 2
View 1 Less Clinical Trial

62 Total Publications

Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study.
Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study.
Journal: NPJ precision oncology
Published: March 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xiao's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile